Estimated owner-operator benefit for a mature franchised Stand-Alone unit. The range combines 2025 Item 19 Gross Revenue quartile medians with an official U.S. medical-laboratory net-income margin proxy. A separately modeled mature Micro Market produces about $15,600-$33,000. Any Lab Test Now does not report owner earnings, operating profit, EBITDA, or net income in Item 19.
This is an independent analytical scenario, not an Item 19 financial performance representation by Any Test Franchising, LLC. It combines identified facts from the 2026 Franchise Disclosure Document with a separately identified IRS benchmark and explicit sensitivity assumptions. Actual results can differ materially by location, format, Gross Revenue, test mix, labor, occupancy, financing, owner involvement, local advertising, and execution.
- Legal franchisor
- Any Test Franchising, LLC.
- Current disclosure
- Any Lab Test Now 2026 Franchise Disclosure Document, issued April 20, 2026; Item 19, pp. 37-39; Items 6, 15, and 20 also used. No matching public FDD was located on the franchisor-controlled website, so the FDD citations are unlinked.
- Applicable populations
- 213 mature franchised Stand-Alone businesses and 17 mature franchised Micro Market businesses operating continuously through the 2025 reporting period. Affiliate-operated results remain separate.
- Official supplemental evidence
- Any Lab Test Now U.S. franchise website, IRS nonfarm sole-proprietorship statistics, and U.S. Bureau of Labor Statistics wage data.
- Date checked
- July 15, 2026.
The same-brand FDD supplies a broad and clearly defined Gross Revenue distribution, but the owner-benefit conversion relies materially on a broader 2022 IRS industry proxy and editorial margin sensitivity. The estimate is therefore useful for screening, not underwriting.
What does the strongest evidence actually measure?
Officially, Item 19 measures 2025 Gross Revenue, not owner income. For the Stand-Alone format, it divides 213 franchised businesses into revenue quartiles. Each business had to be open and continuously operating for the full January 1-December 31, 2025 reporting period and for at least one full calendar year by year-end.
The disclosed Gross Revenue definition covers receipts from services and products, less receipts from toxicology employer services that the system no longer offers. The figures came from unaudited franchisee reports. Item 19 excluded 17 franchised Stand-Alone businesses opened during 2025, including one that opened and closed; eight other Stand-Alone businesses that closed during the year; and all 17 Micro Market businesses from the Stand-Alone table.
| 2025 franchised Stand-Alone cohort | Units | Average Gross Revenue | Median Gross Revenue |
|---|---|---|---|
| Top 25% | 54 | $547,428 | $533,743 |
| 26%-50% | 53 | $339,562 | $334,660 |
| 51%-75% | 53 | $241,519 | $242,522 |
| Bottom 25% | 53 | $152,590 | $154,665 |
Official source: Any Lab Test Now 2026 FDD, Item 19, pp. 37-38. The FDD also reports a $137,230 average and $133,551 median for 17 franchised Micro Market businesses, plus separate results for seven affiliate-operated Stand-Alone businesses. Those populations are not combined here.
Item 19's 44.5%-93% estimated gross margins for seven selected laboratory tests are test-level retail-price-minus-cost-of-goods calculations based on 2026 projections. They do not deduct center labor, occupancy, royalty, advertising, technology, insurance, professional services, or other operating costs, so they cannot be treated as store-level profit margins.
The FTC Franchise Rule Compliance Guide explains the framework for financial performance representations. For this brand, the practical boundary is clear: Item 19 supports revenue comparisons and selected test gross margins, but not a claim about annual owner earnings.
How were the annual owner-earnings scenarios calculated?
The model multiplies format-specific FDD revenue anchors by a 14.6%-20.6% owner-operator benefit margin band. The central 17.6% proxy equals IRS 2022 net income less deficit of $238.974 million divided by $1.356872 billion of business receipts for 21,341 sole-proprietor medical and diagnostic laboratory returns. The conservative and upside sensitivities are the benchmark minus and plus three percentage points.
$242,522 revenue anchor multiplied by the 17.6% IRS proxy.
Official $133,551 median revenue multiplied by the 17.6% proxy.
Median Gross Revenue for the FDD's 51%-75% quartile.
Medical and diagnostic laboratory sole proprietorships, Tax Year 2022.
Mature franchised units open continuously throughout 2025.
Current royalty and national fund, plus annual local advertising and technology.
The IRS measure is an all-in net-income statistic. Sole proprietors do not deduct a salary paid to themselves, so the result is closer to owner-operator benefit than passive business profit. It includes depreciation and interest deductions to the extent reported in the IRS data. It excludes personal income taxes and financing principal payments; cash capital expenditures are not separately modeled.
The model does not subtract the FDD's recurring charges a second time because the IRS ratio is already an all-in net-income measure and its “other business expenses” may contain franchise-like costs for some returns. That avoids mechanical double-counting, but creates a material comparability limitation: the IRS population is broader than retail specimen-collection centers and does not isolate Any Lab Test Now franchisees. See the IRS Sole Proprietorship Returns, Tax Year 2022 report, Table 1 and Table 2.
| Stand-Alone scenario | FDD revenue anchor | Margin assumption | Estimated owner-operator benefit |
|---|---|---|---|
| Conservative | Bottom-quartile median: $154,665 | 14.6% | $22,600 |
| Base | 51%-75% quartile median: $242,522 | 17.6% | $42,700 |
| Upside | Top-quartile median: $533,743 | 20.6% | $110,000 |
The labels are analytical scenarios, not probabilities. “Base” is not presented as the most likely result. Revenue anchors are official; margin sensitivities and resulting owner benefits are independent estimates. Dollar results are rounded to the nearest $100.
The model's earnings range is driven by both the disclosed revenue band and a six-percentage-point margin sensitivity.
Interpretation: Gross Revenue is the dominant driver; the top-quartile median revenue anchor is more than three times the bottom-quartile median.
Sources: Any Lab Test Now 2026 FDD, Item 19, pp. 37-39; IRS Statistics of Income, medical and diagnostic laboratories, Tax Year 2022. Calculations: revenue × 14.612%, 17.612%, or 20.612%; rounded to nearest $100.
What changes for a Micro Market?
A mature franchised Micro Market produces a narrower estimated owner-operator benefit range of about $15,600-$33,000. Item 19 provides one median rather than quartiles, so the revenue spread below is an explicit analytical assumption: 80%, 100%, and 120% of the official $133,551 median. It is not a franchisor-reported distribution.
| Micro Market scenario | Revenue assumption | Margin assumption | Estimated owner-operator benefit |
|---|---|---|---|
| Conservative | $106,841 | 14.6% | $15,600 |
| Base | $133,551 | 17.6% | $23,500 |
| Upside | $160,261 | 20.6% | $33,000 |
The FDD reports a $37,405-$420,367 Micro Market Gross Revenue range across 17 units, but it does not provide quartiles. The 80%/100%/120% spread is used to avoid treating two extreme endpoints as ordinary scenario anchors.
How does owner involvement change the economics?
Owner involvement can determine whether the modeled result is compensation for work or residual business profit. The 2026 FDD allows a trained owner or trained manager to directly supervise and participate in day-to-day operations. However, the brand's current official first-unit candidate requirements state that the first location must be operated by a full-time owner/operator.
The IRS sole-proprietor margin does not deduct an owner's salary. Accordingly, the $23,000-$110,000 Stand-Alone range should be read as estimated owner-operator benefit: residual net income plus the economic value of the owner's labor embedded in that result. It is not passive profit.
The $69,680 benchmark is a wage-only stress test from the BLS Occupational Outlook Handbook. It excludes employer payroll taxes and benefits, and the occupation is broader and often more senior than a single retail lab-center manager. Local hiring costs could be materially lower or higher. The BLS OEWS tables should be checked for the buyer's state and metropolitan area.
Subtracting a wage-only manager benchmark turns the lower two Stand-Alone scenarios negative and leaves a positive residual only in the upside scenario.
Interpretation: A manager-run structure requires substantially more unit-level cash flow than an owner-operated structure. Negative residuals are analytical stress-test results, not forecasts of actual losses.
Sources: Stand-Alone owner-operator scenarios above; BLS Medical and Health Services Managers, May 2024 lower-10th-percentile wage of $69,680. Manager payroll taxes, benefits, and recruiting costs are excluded, so actual employer cost would generally be higher.
For a first unit, the evidence supports evaluating the opportunity as an active operating role. A buyer should not convert the owner-operator benefit into a “salary plus profit” claim unless the unit's actual books separately identify owner wages, manager wages, distributions, retained earnings, and normalized operating profit.
Which contractual costs can compress owner earnings?
The 7% royalty, current 2% National Marketing Fund contribution, local advertising floor, and technology fee create a meaningful recurring burden before ordinary center expenses. Item 6 applies these obligations to both formats, with different fixed local-advertising requirements.
| Recurring obligation | Stand-Alone | Micro Market | Owner-earnings treatment |
|---|---|---|---|
| Royalty Fee | 7% of Gross Revenue; $500 monthly minimum | Same | Ongoing percentage charge |
| National Marketing Fund | Currently 2% of Gross Revenue; may rise to 3% | Same | Ongoing percentage charge |
| Local Advertising Requirement | $2,000 monthly / $24,000 annually | $750 monthly / $9,000 annually | Required operating spend |
| Technology Fee | $350 monthly / $4,200 annually; contractual cap $600 monthly | Same | Required operating fee |
| Physician Processing Fee | Up to $2 per requisition and/or injection | Same | Volume-dependent; not modeled |
| Advertising cooperative / multi-area marketing | 1%-3% if implemented; none in effect at issuance | Same | Potential additional burden |
Official source: Any Lab Test Now 2026 FDD, Item 6, pp. 7-8. “Required operating spend” is not necessarily paid to the franchisor, but it still reduces cash available to the owner.
At the selected $242,522 Stand-Alone base revenue anchor, 9% of Gross Revenue plus $24,000 of local advertising and $4,200 of technology equals about $50,027, or 20.6% of revenue. At the $133,551 Micro Market median, 9% plus $9,000 and $4,200 equals about $25,220, or 18.9%. These are contractual charge-and-spend diagnostics, not additional deductions from the all-in IRS-margin scenario.
What uncertainty should a buyer resolve before relying on the range?
The largest unresolved uncertainty is the actual unit-level expense structure after the FDD's recurring obligations. Item 19 does not show center labor, occupancy, insurance, merchant processing, supplies, professional fees, bad debt, depreciation, interest, manager compensation, owner compensation, or normalized operating profit.
Item 20 adds population context, not earnings evidence. During 2025, the franchised system opened 18 outlets, eight ceased operations for “other reasons,” and the year-end franchised count rose from 237 to 247. Closed and newly opened units are absent from the mature Stand-Alone revenue cohort, and Item 20 does not disclose their profit or loss.
- Request Item 19 written substantiation. Reconcile the 2025 Gross Revenue reports to the exact Stand-Alone or Micro Market format, opening date, and ownership model being considered.
- Interview both current and former franchisees. Ask for normalized labor, rent, local advertising, technology, physician-processing, insurance, supplies, and owner-hours data rather than a single “take-home” number.
- Separate owner labor from business profit. Identify what a qualified replacement manager would cost locally, including payroll taxes and benefits.
- Test the royalty minimum and fixed advertising burden at low sales. Percentage fees become less important at lower revenue than the fixed $24,000 or $9,000 local-spend floor and technology charge.
- Model debt separately. Item 10 says the franchisor does not offer or guarantee financing. Financing principal is outside this earnings estimate, and interest treatment will depend on the buyer's loan structure.
- Verify maintenance capital and working capital. Depreciation appears in the IRS proxy, but the scenario does not calculate actual equipment replacement, remodel, or cash capital-expenditure timing.
- Do not estimate personal taxes from this range. Entity structure, state and local tax, deductions, other income, and owner circumstances determine after-tax cash.
What is the decision-useful owner-earnings takeaway?
The strongest defensible screening range is approximately $23,000-$110,000 of annual pre-tax owner-operator benefit for a mature Stand-Alone unit, with a separate $15,600-$33,000 Micro Market range. Both are scenario-based, not official earnings disclosures. Gross Revenue is the most important modeled driver; the largest unresolved variable is the unit's true all-in operating margin after labor, occupancy, recurring franchise obligations, and owner-role choices.
A manager-run structure is not supported as passive income by the evidence and may require top-quartile economics merely to leave a positive residual after a market manager wage. Before making a decision, the buyer should verify Item 19 substantiation, obtain format-specific profit-and-loss evidence from existing and former franchisees, and reconcile owner compensation, manager compensation, debt service, and capital spending separately.